checkAd

     111  0 Kommentare Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer - Seite 4

    Investor Contacts:
    Christopher Degnan
    Galera Therapeutics, Inc.
    610-725-1500
    cdegnan@galeratx.com

    Jennifer Porcelli
    Solebury Trout
    646-378-2962
    jporcelli@soleburytrout.com

    Lesen Sie auch

    Media Contact:
    Gina Cestari
    6 Degrees
    917-797-7904
    gcestari@6degreespr.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 4 von 4

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer - Seite 4 Company Updates Guidance for Topline Data Readout to ASTRO 2020MALVERN, Pa., Sept. 08, 2020 (GLOBE NEWSWIRE) - Galera Therapeutics, Inc. (Nasdaq: GRTX), is a clinical-stage biopharmaceutical company focused on developing and commercializing a …